Oncology: partnership agreement with Roche
December 20, 2013
Roche and Pierre Fabre Médicament have signed an agreement for the promotion and provision of scientific information for patent medicine NeoRecormon® (indicated in haematology) in France to oncologists and haematologists.
From 1 January 2014 Pierre Fabre Oncologie will be in charge of promoting the correct use of the medicine, as well as scientific information activities for French haematologists and oncologists. Roche will remain the holder of the MA and will continue to fulfil its obligations, in particular with regard to pharmacovigilance.
With Navelbine® oral, Javlor® and Busilvex®, Pierre Fabre is a recognised player in oncology and haematology, in particular for lung, breast, and bladder cancers and in the bone marrow transplant conditioning phase. We are delighted to announce this new partnership with Roche which enables us to add to the portfolio of therapeutic medicines available to French haematologists and oncologists. The president of Pierre Fabre Médicament, Mr Frédéric Duchesne, declared that this project is fully in line with our strategy to make oncology one of the Group’s priority franchises.